cilengitide has been researched along with N-methyl-N-[2-[[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]phenyl]methanesulfonamide in 1 studies
Studies (cilengitide) | Trials (cilengitide) | Recent Studies (post-2010) (cilengitide) | Studies (N-methyl-N-[2-[[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]phenyl]methanesulfonamide) | Trials (N-methyl-N-[2-[[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]phenyl]methanesulfonamide) | Recent Studies (post-2010) (N-methyl-N-[2-[[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]phenyl]methanesulfonamide) |
---|---|---|---|---|---|
194 | 29 | 133 | 8 | 0 | 4 |
Protein | Taxonomy | cilengitide (IC50) | N-methyl-N-[2-[[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]phenyl]methanesulfonamide (IC50) |
---|---|---|---|
Chain A, Protein tyrosine kinase 2 beta | Homo sapiens (human) | 0.011 | |
Chain A, Protein tyrosine kinase 2 beta | Homo sapiens (human) | 0.011 | |
Chain A, Protein tyrosine kinase 2 beta | Homo sapiens (human) | 0.011 | |
Androgen receptor | Rattus norvegicus (Norway rat) | 0.011 | |
Focal adhesion kinase 1 | Homo sapiens (human) | 0.0013 | |
Protein-tyrosine kinase 2-beta | Homo sapiens (human) | 0.0294 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Allen, JG; Babij, P; Fotsch, C | 1 |
1 review(s) available for cilengitide and N-methyl-N-[2-[[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]phenyl]methanesulfonamide
Article | Year |
---|---|
Emerging targets in osteoporosis disease modification.
Topics: Animals; Biomarkers; Bone Density; Bone Resorption; Humans; Osteoporosis | 2010 |